论文部分内容阅读
一项剂量递增的Ⅰ期临床试验结果显示,dasatinib(大沙替尼)药物可使具有imatinib抗药性或不耐受的慢性髓细胞性白血病(CML)和费氏染色体阳性急性淋巴细胞白血病(Ph+ALL)患者的临床治疗成为可能。该研究结果已在第47届美国血液病学年会(ASH)上发布。研究人员报道说,此前作为临床一线药物的Imatinib曾在CML治疗上产生过新的变革,该药可使不足50%的患者5年存活率提高至90%左右;尽管大多数患者治疗反应稳定,但少数患者会在初期治疗反应后出现抗药性;甚至在第5年治疗时,其
A dose-escalation phase I trial showed that dasatinib (dasatinib) drugs can cause chronic myelogenous leukemia (CML) with imatinib resistance or intolerance and Fibronectin positive acute lymphoblastic leukemia (Ph + ALL) clinical treatment of patients possible. The results of this study have been published at the 47th American Society of Hematology (ASH). Researchers have reported that Imatinib, a previous first-line clinical drug, has undergone a revolution in CML that increases the 5-year survival rate to about 90% in less than 50% of patients; and although most patients respond well to treatment, However, a minority of patients develop resistance after the initial treatment response; even at the fifth year of treatment,